Pleural mesothelioma’s aggressive nature and complex anatomical considerations often limit treatment options; hence, surgery’s role remains contentious. The recent study from Mount Sinai counters the skepticism generated by the Mesothelioma and Radical Surgery 2 (MARS2) trial, conducted in 2024, which questioned the value and safety of radical surgical interventions. Unlike MARS2, where higher early postoperative mortality rates were reported, the Mount Sinai cohort experienced zero in-hospital and 30-day mortality and only a 4.2 percent mortality rate at 90 days post-surgery. This stark contrast elucidates the critical role of patient selection, surgical technique refinement, and comprehensive preoperative evaluation.

At the heart of this study’s success is the surgical technique of pleurectomy/decortication. This procedure intricately removes the diseased pleural lining and tumor masses while sparing the underlying lung parenchyma, thereby preserving pulmonary function. Such an approach significantly reduces surgical morbidity compared to extrapleural pneumonectomy, an older, more radical operation that entails removing the lung along with the pleura, diaphragm, and pericardium. Mount Sinai’s data reinforce that organ preservation should be prioritized where feasible, as it offers a meaningful balance between oncologic control and patient quality of life.

The study’s senior author, Dr. Raja M. Flores, a distinguished Professor of Surgery and Chair of Thoracic Surgery at Mount Sinai, underscores that the outcomes hinge not merely on the surgical procedure itself but on the nuanced selection of appropriate candidates. Over nearly two decades, Dr. Flores has been a pioneer in thoracic oncology research, having previously demonstrated that pleurectomy/decortication confers superior survival benefits when compared to more extensive surgeries in mesothelioma patients. This trajectory reflects an evolving understanding of mesothelioma surgery from purely oncologic aggressiveness toward personalized, patient-centric care.

Integral to these improved outcomes is the use of advanced imaging modalities and rigorous preoperative screening protocols. Modern diagnostic imaging enables precise tumor staging and identification of the epithelioid subtype of mesothelioma, which comprised nearly 80 percent of patients in the Mount Sinai cohort. This histologic subtype is associated with better surgical outcomes, and its prevalence likely influenced the favorable postoperative mortality observed. Furthermore, the study excluded patients considered for extrapleural pneumonectomy, thereby focusing on a population more amenable to lung-sparing surgery and less susceptible to severe surgical complications.

This paradigm shift reflects a broader transformation within thoracic oncology, wherein surgical candidacy is now contingent on multidimensional patient evaluation encompassing functional status, tumor biology, and individual risk profiles. Mount Sinai’s meticulous approach includes rigorous pulmonary and cardiac assessments, ensuring only those patients who can tolerate the extensive surgical procedure and recovery are offered pleurectomy/decortication. This tailored methodology contrasts with earlier trials like MARS2 and may account for divergent outcomes and interpretations regarding surgery’s efficacy.

An important contextual element is mesothelioma’s overarching clinical challenge: its limited responsiveness to traditional therapeutic modalities such as chemotherapy and radiation. This therapeutic void accentuates the urgency for surgical innovation that can safely extend survival and maintain quality of life. The Mount Sinai study, therefore, represents a significant advance by not only supporting surgery’s potential role but also establishing new benchmarks for its implementation in multidisciplinary treatment regimens.

The implications of these findings extend beyond immediate surgical outcomes. The team at Mount Sinai is currently exploring the integration of immunotherapy with surgical strategies to further enhance treatment efficacy. Preliminary investigations suggest that combining lung-sparing surgery with immune checkpoint inhibitors could potentiate anti-tumor responses, offering a promising frontier in mesothelioma management. This ongoing research underscores the institution’s commitment to translating benchside discoveries into clinical realities with tangible patient benefits.

Another notable aspect of Mount Sinai’s legacy in mesothelioma research is its historical link to Dr. Irving J. Selikoff, whose pioneering studies first established asbestos exposure as the etiologic agent in mesothelioma. His work catalyzed regulatory policies that curtailed asbestos use worldwide, thereby offering primary prevention. Today, Mount Sinai continues this legacy through comprehensive patient care programs, including those addressing mesothelioma cases linked to environmental exposures such as the World Trade Center disaster.

The study’s findings, emphasizing safety and tailored surgical care, offer renewed hope to patients and clinicians navigating the difficult terrain of pleural mesothelioma treatment. Dr. Flores articulates the essential message succinctly: while surgery may not be suitable for every patient, for carefully selected individuals at experienced centers, it remains a vital and viable path to prolonged survival. This perspective advocates for surgical consideration to remain a pivotal component of mesothelioma care discussions.

In conclusion, these contemporary outcomes from Mount Sinai challenge the prevailing skepticism about the surgical management of pleural mesothelioma. They underscore that with state-of-the-art imaging, stringent patient selection, and lung-preserving techniques, pleurectomy/decortication can be safely employed with minimum early mortality and optimal therapeutic benefit. This study not only advances surgical science but also offers a beacon for evidence-based, patient-centered oncology in the face of one of the most daunting thoracic malignancies.

Subject of Research: People

Article Title: Disaster on MARS2? Lessons Learned from Modern Day Outcomes of Surgery for Pleural Mesothelioma

News Publication Date: 2-Feb-2026

Web References:

• DOI: 10.1016/j.athoracsur.2026.01.025
• MARS2 trial full text: The Lancet Respiratory Medicine

Image Credits: Mount Sinai Health System

Keywords: Mesothelioma, Lung cancer

Chimeric Antigen Receptor (CAR) T-cell therapy, a revolutionary immunotherapeutic technique, reprograms a patient’s own immune cells to recognize and eradicate malignant cells with remarkable specificity and efficacy. With its transformative impact on multiple myeloma, CAR T-cell therapy targeting B-cell maturation antigen (BCMA) has entered the therapeutic arsenal as a beacon of hope for patients with otherwise refractory disease. However, despite its profound benefits, this therapy carries risks of unforeseen adverse outcomes, including the emergence of secondary cancers, such as T-cell lymphomas, a scenario that poses significant clinical challenges and demands innovative solutions.

The case under study involves a 51-year-old patient who achieved complete remission of multiple myeloma following anti-BCMA CAR T-cell infusion. Unfortunately, the patient subsequently developed an aggressive CAR-positive T-cell lymphoma characterized by rapid progression and multifocal involvement encompassing the skin, peripheral blood, and bone marrow. This clinical conundrum presented a rare but critical opportunity to explore novel therapeutic avenues against such secondary hematologic malignancies that defy conventional treatment paradigms.

Employing sophisticated genomic and immunologic profiling platforms developed within Mount Sinai’s research infrastructure, investigators conducted an exhaustive characterization of the lymphoma’s molecular landscape. These analyses enabled the identification of aberrant cellular pathways and surface markers that could serve as actionable therapeutic targets. Their strategy incorporated leveraging Food and Drug Administration (FDA)-approved compounds, thereby facilitating expedited clinical translation and circumventing the extensive timelines typically necessary for new drug development.

Central to this therapeutic triumph was the novel application of an anti-CCR4 (CC chemokine receptor 4) antibody. Traditionally not utilized in this context, the antibody demonstrated selective cytotoxicity against the malignant T-cell population expressing this receptor, effectively eradicating the lymphoma. This targeted immunotherapy not only eliminated the T-cell lymphoma but was also well-tolerated, ensuring sustained remission without compromising prior control of the patient’s myeloma. This dual disease remission embodies a critical milestone, affirming the feasibility of using precision immunotherapeutic strategies against complex CAR T-cell therapy-induced malignancies.

Dr. Samir Parekh, MD, Director of the Center of Excellence for Multiple Myeloma at Mount Sinai and senior author on the study, emphasized the broader implications of this case. He highlighted the necessity for vigilant monitoring for secondary cancers post-CAR T therapy and underscored the vital role of precision medicine frameworks in rapidly tailoring effective interventions. This case impeccably illustrates the evolving understanding that therapeutic modalities must adapt dynamically to the biological intricacies introduced by innovative cancer treatments.

The investigative team’s work represents a multidisciplinary effort uniting experts in molecular biology, immunology, genomics, and clinical oncology. Collaborators included the laboratories of Joshua Brody, MD, Patrick Brunner, MD, MSc, and The Parekh Lab, alongside the Icahn Genomics Institute and multiple departments within the Icahn School of Medicine. This convergence of expertise was pivotal in unraveling the complex pathobiology of secondary CAR-positive T-cell lymphomas and delineating targeted treatment strategies.

This research also underscores the necessity for the development of next-generation CAR T therapies with enhanced safety profiles designed to minimize immunogenic and oncogenic sequelae. Mount Sinai’s ongoing efforts aim to refine CAR T-cell constructs and optimize patient monitoring protocols, ultimately striving to mitigate the incidence of such rare but devastating side effects. The future of hematologic cancer therapy hence lies in harmonizing potent antitumor efficacy with maximal patient safety.

Notably, the identification of anti-CCR4 antibody as an effective agent marks a significant advancement in the expanding repertoire of immunotherapeutic options available for T-cell malignancies. CCR4, a chemokine receptor implicated in T-cell migration and tumor microenvironment interactions, represents an attractive target for selective immunomodulation. By harnessing existing FDA-approved drugs in novel clinical contexts, researchers have opened promising avenues for rapid therapeutic innovation that could extend beyond this unique case.

The success documented here lays a foundational precedent for addressing secondary malignancies arising from immunotherapy, a challenge that is anticipated to become more prevalent as these treatments deepen their footprint across oncologic indications. This paradigm advocates for comprehensive molecular profiling and adaptive treatment planning as cornerstones of modern cancer care, envisioning personalized strategies to circumvent therapy resistance and emergent complications.

In conclusion, this dramatic clinical success story not only illuminates the path toward conquering rare CAR-positive T-cell lymphomas induced by CAR T-cell therapy but also exemplifies the synergistic potential of translational research in revolutionizing patient outcomes. As immunotherapy continues to reshape cancer treatment landscapes, stories like this reinforce the critical importance of vigilance, flexibility, and innovation in managing the intricate balance between therapeutic benefit and risk.

Subject of Research: People
Article Title: Targeted Therapy of CAR+ T-Cell Lymphoma after Anti-BCMA CAR T-Cell Therapy
News Publication Date: 21-Aug-2025
Web References:

• New England Journal of Medicine, DOI: 10.1056/NEJMc2504588
  Keywords: Cancer treatments, Multiple myeloma